Thermo Fisher Scientific Inc. (NYSE:TMO) reported better-than-expected first-quarter financial results and raised its FY24 guidance on Wednesday. Thermo Fisher Scientific posted a first-quarter revenue of $10.34 billion, down 3% year over year, beating the consensus of $10.17 billion. Adjusted EPS of $5.11 beat the consensus of $4.71 and grew from $5.03 a year ago, according to data from Benzinga Pro. Revenue from the Life Sciences Solutions Segment declined by 12.5% to $2.29 billion. Analytical Instruments Segment sales were down 2.1% to $1.69 billion. Specialty Diagnostics Segment revenues were almost flat at $1.1 billion, and Laboratory ...